Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

NCT ID: NCT00690378

Last Updated: 2018-05-25

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

137 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complicated Urinary Tract Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

NXL/104 ceftazidime

Group Type EXPERIMENTAL

NXL104/ceftazidime

Intervention Type DRUG

125mg/500mg TID

2

comparator 4 x daily

Group Type ACTIVE_COMPARATOR

Imipenem/Cilastatin

Intervention Type DRUG

4 x daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NXL104/ceftazidime

125mg/500mg TID

Intervention Type DRUG

Imipenem/Cilastatin

4 x daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute pyelonephritis or other complicated urinary tract infection due to gram negative pathogens

Exclusion Criteria

* ileal loops or vesicoureteral reflux
* complete obstruction of any portion of urinary tract, perinephric or intrarenal abscess.
* fungal urinary tract infection
* permanent indirect catheter or nephrostomy unless removed within 48 hours of study entry
* history hypersensitivity to study medication
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Carole A Sable, MD

Role: STUDY_DIRECTOR

Novexel Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Research Center

Birmingham, Alabama, United States

Site Status

Southeast Alabama Medical Center

Dothan, Alabama, United States

Site Status

Providence Hospital

Mobile, Alabama, United States

Site Status

Arizona Pulmonary Specialists LTD

Phoenix, Arizona, United States

Site Status

Sharp Chula Vista Medical Center

Chula Vista, California, United States

Site Status

Synergy Clinical Research Center

Escondido, California, United States

Site Status

Novellus Research Sites

Fountain Valley, California, United States

Site Status

Novellus Research Sites

Long Beach, California, United States

Site Status

Modesto Clinical Research

Modesto, California, United States

Site Status

Tri City Medical Center

Oceanside, California, United States

Site Status

EStudy Site

San Jose, California, United States

Site Status

Olive View UCLA Medical Center

Sylmar, California, United States

Site Status

Christiana Care Health Services

Newark, Delaware, United States

Site Status

Century Clinical Research, Inc

Daytona Beach, Florida, United States

Site Status

University of Florida

Jacksonville, Florida, United States

Site Status

Southeast Regional Research Group

Columbus, Georgia, United States

Site Status

St. Joseph's/Candler Health System

Savannah, Georgia, United States

Site Status

Four Rivers Clinical Research Inc

Paducah, Kentucky, United States

Site Status

Louisiana State University Health Services Ctr Shreveport

Shreveport, Louisiana, United States

Site Status

R. Adams Cowley Shock Trauma Center

Baltimore, Maryland, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

North Memorial Medical Center

Minneapolis, Minnesota, United States

Site Status

Saint Louis University Hospital

St Louis, Missouri, United States

Site Status

St. James Healthcare

Butte, Montana, United States

Site Status

Jersey Shore University Medical Center

Neptune City, New Jersey, United States

Site Status

Newark Beth Israel Medical Center

Newark, New Jersey, United States

Site Status

University Hospital UMDNJ

Newark, New Jersey, United States

Site Status

Albany Medical Center

Albany, New York, United States

Site Status

Brookdale University Hospital

Brooklyn, New York, United States

Site Status

Vassar Brothers Medical Center

Poughkeepsie, New York, United States

Site Status

Staten Island University Hospital

Staten Island, New York, United States

Site Status

Mission Hospital

Asheville, North Carolina, United States

Site Status

Clinical Trials of America Inc.

Winston-Salem, North Carolina, United States

Site Status

Summa Health System Hospitals

Akron, Ohio, United States

Site Status

Remington-Davis

Columbus, Ohio, United States

Site Status

Regional Infectious Disease-Infusion Center

Lima, Ohio, United States

Site Status

St Vincent's Mercy Medical Center

Toledo, Ohio, United States

Site Status

Thomas Jefferson Univ Hospital

Philadelphia, Pennsylvania, United States

Site Status

Reading Hospital and Medical Center

West Reading, Pennsylvania, United States

Site Status

Harris Methodist

Azle, Texas, United States

Site Status

University of Texas MD Anderson

Houston, Texas, United States

Site Status

Sentara Norfold General Hospital

Norfolk, Virginia, United States

Site Status

Al-Essra hospital

Amman, , Jordan

Site Status

Al-Islami Hospital

Amman, , Jordan

Site Status

Jordan University Hospital

Amman, , Jordan

Site Status

King Abdullah University Hospital

Irbid, , Jordan

Site Status

Clinique due Levant Hospital

Beirut, , Lebanon

Site Status

Dr. Rizk Clinic

Beirut, , Lebanon

Site Status

Makassed General Hospital

Beirut, , Lebanon

Site Status

Rafik Hariri University Hospital

Beirut, , Lebanon

Site Status

Sahel General Hospital

Beirut, , Lebanon

Site Status

Notre Dame Des Secours Hospital

Byblos, , Lebanon

Site Status

Ain Wazein Hospital

Chouf, , Lebanon

Site Status

St. Joseph Hospital

Ed Daoura, , Lebanon

Site Status

Mount Lebanon Hospital

Hazmiyeh, , Lebanon

Site Status

Nabatyeh Governmental Hospital

Nabatyeh, , Lebanon

Site Status

Hammoud Hospital University Medical Center

Saida, , Lebanon

Site Status

Labib Medical Center

Saida, , Lebanon

Site Status

Saida Governmental Hospital

Saida, , Lebanon

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Jordan Lebanon

References

Explore related publications, articles, or registry entries linked to this study.

Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, Sable C. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012 Dec;28(12):1921-31. doi: 10.1185/03007995.2012.748653. Epub 2012 Nov 21.

Reference Type DERIVED
PMID: 23145859 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C3591013

Identifier Type: OTHER

Identifier Source: secondary_id

NXL104/2001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.